Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2023; 29(3): 549-560
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.549
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.549
Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact
Si-Ying Tang, Guan-Huei Lee, Division of Gastroenterology and Hepatology, National University Hospital, Singapore 119228, Singapore
Jian Shiun Tan, Xian-Zheng Pang, Yong Loo Lin School of Medicine, Singapore 117597, Singapore
Author contributions: Tang SY, Tan JS and Pang XZ contributed equally to this work; Tang SY, Tan JS, Pang XZ and Lee GH designed the research study; Tang SY, Tan JS and Pang XZ performed the research; Tang SY, Tan JS, Pang XZ and Lee GH analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guan-Huei Lee, FRCP, MBBS, MRCP, PhD, Assistant Professor, Attending Doctor, Doctor, Division of Gastroenterology and Hepatology, National University Hospital, 1E, Kent Ridge Road, Singapore 119228, Singapore. guan_huei_lee@nuhs.edu.sg
Received: September 24, 2022
Peer-review started: September 24, 2022
First decision: October 30, 2022
Revised: November 14, 2022
Accepted: December 23, 2022
Article in press: December 23, 2022
Published online: January 21, 2023
Peer-review started: September 24, 2022
First decision: October 30, 2022
Revised: November 14, 2022
Accepted: December 23, 2022
Article in press: December 23, 2022
Published online: January 21, 2023
Core Tip
Core Tip: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new definition of fatty liver disease that is based on positive inclusion of metabolic risk factors. Studies have shown that patients included using the MAFLD criteria were associated with higher risks of hepatic fibrosis and all cause mortality when compared to non-alcoholic fatty liver disease.